Furthermore, in some cases, malignant glioma cells evade immunological surveillance by reducing NKG2D ligand expression or cleavage, which may limit the use of NKG2D CAR-T for treating glioblastoma (11). This evidence concerns the gene KLRK1 and malignant glioma.